BE2015C072I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2015C072I2 BE2015C072I2 BE2015C072C BE2015C072C BE2015C072I2 BE 2015C072 I2 BE2015C072 I2 BE 2015C072I2 BE 2015C072 C BE2015C072 C BE 2015C072C BE 2015C072 C BE2015C072 C BE 2015C072C BE 2015C072 I2 BE2015C072 I2 BE 2015C072I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50681203P | 2003-09-29 | 2003-09-29 | |
| PCT/US2004/031326 WO2005032586A1 (en) | 2003-09-29 | 2004-09-24 | Optimized expression of hpv 45 l1 in yeast |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2015C072I2 true BE2015C072I2 (enrdf_load_stackoverflow) | 2023-12-14 |
Family
ID=34421558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2015C072C BE2015C072I2 (enrdf_load_stackoverflow) | 2003-09-29 | 2015-12-09 |
Country Status (33)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| US7858098B2 (en) | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
| MY139500A (en) | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
| WO2005097821A1 (en) | 2004-03-24 | 2005-10-20 | Merck & Co., Inc. | Optimized expression of hpv 52 l1 in yeast |
| US7758866B2 (en) | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
| WO2006113209A1 (en) | 2005-04-15 | 2006-10-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
| CA2606092A1 (en) * | 2005-04-26 | 2006-11-02 | Glaxosmithkline Biologicals S.A. | Vaccine |
| EP2059262B1 (en) * | 2006-08-28 | 2013-08-21 | Sungkyunkwan University Foundation for Corporate Collaboration | A dna vaccine for treating or preventing cervical cancer comprising a gene encoding hpv protein |
| CA2679720A1 (en) * | 2007-03-09 | 2008-09-18 | Merck & Co., Inc. | Papillomavirus vaccine compositions |
| KR101588413B1 (ko) * | 2007-11-23 | 2016-02-02 | 상하이 제런 바이오테크놀러지 코포레이션 리미티드 | 인간 파필로마 바이러스의 주요 캡시드 단백질 ｌ1을 암호화하는 유전자 및 이의 용도 |
| US9566323B2 (en) | 2009-06-19 | 2017-02-14 | Eyegene Inc. | Vaccine for cervical cancer |
| JP6153866B2 (ja) | 2010-05-25 | 2017-06-28 | キアゲン ガイサーズバーグ アイエヌシー． | 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ |
| JP6001064B2 (ja) | 2011-06-15 | 2016-10-05 | チュンアン ユニバーシティー インダストリー アカデミック コアポレイション ファウンデイション | ヒトパピローマウイルスｌ１タンパク質の生産収率を向上させる方法 |
| KR102049988B1 (ko) | 2011-06-24 | 2019-11-28 | 머크 샤프 앤드 돔 코포레이션 | 알루미늄 아주반트를 포함하는 hpv 백신 제제 및 그의 제조 방법 |
| CN109321592A (zh) * | 2012-01-21 | 2019-02-12 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv18 l1蛋白的方法 |
| CN108624614A (zh) * | 2012-03-28 | 2018-10-09 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv11 l1蛋白的方法 |
| CN104120089B (zh) * | 2013-04-26 | 2019-09-24 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv52 l1蛋白的方法 |
| CN110423774A (zh) * | 2013-04-26 | 2019-11-08 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv58 l1蛋白的方法 |
| CN110295190A (zh) * | 2013-05-17 | 2019-10-01 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv45 l1蛋白的方法 |
| CN112280792B (zh) * | 2013-09-29 | 2022-06-24 | 上海泽润生物科技有限公司 | 人乳头瘤病毒基因，及载体，菌株，表达方法 |
| US9782470B2 (en) | 2013-10-16 | 2017-10-10 | Merck Sharp & Dohme Corp. | Method of obtaining thermostable dried vaccine formulations |
| MA40624A (fr) * | 2014-09-11 | 2016-03-17 | Cadila Healthcare Ltd | Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant |
| CN106282278B (zh) * | 2015-06-29 | 2021-06-08 | 广东东阳光药业有限公司 | 一种人乳头瘤病毒l1蛋白的发酵方法 |
| CN106701798B (zh) * | 2015-08-12 | 2021-09-17 | 北京康乐卫士生物技术股份有限公司 | 45型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
| CN109750050B (zh) * | 2017-11-07 | 2023-08-18 | 上海泽润生物科技有限公司 | 重组人乳头瘤病毒45亚型蛋白表达 |
| TW202140069A (zh) | 2020-02-14 | 2021-11-01 | 美商默沙東藥廠 | Hpv疫苗 |
| CN112680462B (zh) * | 2020-12-29 | 2022-02-22 | 上海博唯生物科技有限公司 | 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用 |
| CN113073105B (zh) * | 2021-03-23 | 2023-06-13 | 重庆博唯佰泰生物制药有限公司 | 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用 |
| TW202313658A (zh) | 2021-08-06 | 2023-04-01 | 美商默沙東有限責任公司 | Hpv疫苗 |
| JP2024532127A (ja) | 2021-08-19 | 2024-09-05 | メルク・シャープ・アンド・ドーム・エルエルシー | 熱安定性脂質ナノ粒子およびその使用方法 |
| WO2024254226A1 (en) | 2023-06-09 | 2024-12-12 | Merck Sharp & Dohme Llc | Nanoemulsion adjuvant compositions for human papillomavirus vaccines |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1152935A (zh) * | 1994-05-16 | 1997-06-25 | 麦克公司 | 乳头状瘤病毒疫苗 |
| AR004464A1 (es) | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
| IL117459A (en) * | 1995-03-22 | 2005-11-20 | Merck & Co Inc | Dna encoding human papillomavirus type 18 |
| IL117591A0 (en) * | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
| WO1998034640A2 (en) | 1997-02-07 | 1998-08-13 | Merck & Co., Inc. | Synthetic hiv gag genes |
| DE69732378D1 (de) * | 1997-05-27 | 2005-03-03 | Hanil Synthetic Fiber Co Ltd | Verfahren zur herstellung von rekombinanten eiweissen durch verwendung von hocheffizienten expressionsvektoren aus saccharomyces cerevisiae |
| CA2296067C (en) | 1997-07-09 | 2008-10-07 | The University Of Queensland | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
| AU760633B2 (en) * | 1998-08-14 | 2003-05-22 | Merck Sharp & Dohme Corp. | Process for purifying human papillomavirus virus-like particles |
| US6991795B1 (en) * | 1998-08-14 | 2006-01-31 | Merck & Co., Inc. | Protein delivery system using human papillomavirus virus-like particles |
| JP4563582B2 (ja) * | 1998-08-14 | 2010-10-13 | メルク・シャープ・エンド・ドーム・コーポレイション | ヒトパピローマウイルスのウイルス様粒子を使用するタンパク質送達系 |
| ES2237204T3 (es) * | 1998-12-23 | 2005-07-16 | MERCK & CO., INC. | Ensayo de neutralizacion usando particulas similares al virus de papilomavirus humano. |
| PT1212358E (pt) * | 1999-08-25 | 2005-04-29 | Merck & Co Inc | Genes sinteticos de papilomavirus humano |
| US6436402B1 (en) * | 1999-10-15 | 2002-08-20 | Merck & Co., Inc. | Process for making human papillomavirus virus-like particles with improved properties |
| US7026443B1 (en) * | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
| KR100874552B1 (ko) | 2000-07-21 | 2008-12-16 | 글락소 그룹 리미티드 | 코돈-최적화 파필로마 바이러스 서열 |
| US20040063188A1 (en) * | 2002-02-14 | 2004-04-01 | Novavax, Inc. | Kit for treating gastrointestinal tract |
| GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| CA2519112C (en) | 2003-03-24 | 2012-09-11 | Merck & Co., Inc. | Optimized expression of hpv 31 l1 in yeast |
-
2004
- 2004-09-21 MY MYPI20043867A patent/MY140664A/en unknown
- 2004-09-22 AR ARP040103420A patent/AR045804A1/es active IP Right Grant
- 2004-09-23 TW TW093128883A patent/TWI350853B/zh not_active IP Right Cessation
- 2004-09-24 PL PL04788982T patent/PL1673106T3/pl unknown
- 2004-09-24 NZ NZ545834A patent/NZ545834A/en not_active IP Right Cessation
- 2004-09-24 DE DE602004021828T patent/DE602004021828D1/de not_active Expired - Lifetime
- 2004-09-24 RU RU2006114701/13A patent/RU2360001C2/ru active
- 2004-09-24 ES ES04788982T patent/ES2327530T3/es not_active Expired - Lifetime
- 2004-09-24 EP EP04788982A patent/EP1673106B1/en not_active Expired - Lifetime
- 2004-09-24 AU AU2004277934A patent/AU2004277934B2/en active Active
- 2004-09-24 WO PCT/US2004/031326 patent/WO2005032586A1/en active Application Filing
- 2004-09-24 KR KR1020067006044A patent/KR101165278B1/ko not_active Expired - Lifetime
- 2004-09-24 DK DK04788982T patent/DK1673106T3/da active
- 2004-09-24 CA CA2539168A patent/CA2539168C/en not_active Expired - Lifetime
- 2004-09-24 MX MXPA06003457A patent/MXPA06003457A/es active IP Right Grant
- 2004-09-24 US US10/573,330 patent/US7250170B2/en not_active Expired - Lifetime
- 2004-09-24 AT AT04788982T patent/ATE435029T1/de active
- 2004-09-24 CN CN2004800281067A patent/CN1859923B/zh not_active Expired - Lifetime
- 2004-09-24 SI SI200431180T patent/SI1673106T1/sl unknown
- 2004-09-24 BR BRPI0414845A patent/BRPI0414845B8/pt not_active IP Right Cessation
- 2004-09-24 JP JP2006528190A patent/JP5451960B2/ja not_active Expired - Lifetime
- 2004-09-24 PT PT04788982T patent/PT1673106E/pt unknown
-
2006
- 2006-03-08 ZA ZA200601961A patent/ZA200601961B/en unknown
- 2006-03-20 IS IS8362A patent/IS2694B/is unknown
- 2006-03-21 IL IL174458A patent/IL174458A/en active IP Right Grant
- 2006-04-28 NO NO20061876A patent/NO339932B1/no active Protection Beyond IP Right Term
-
2007
- 2007-05-23 US US11/805,453 patent/US7482015B2/en not_active Expired - Lifetime
-
2009
- 2009-09-21 CY CY20091100973T patent/CY1110525T1/el unknown
-
2010
- 2010-07-07 AR ARP100102440A patent/AR077396A2/es not_active Application Discontinuation
-
2011
- 2011-03-02 JP JP2011045589A patent/JP2011152137A/ja active Pending
-
2014
- 2014-06-24 JP JP2014129350A patent/JP2014221052A/ja active Pending
-
2015
- 2015-11-30 NL NL300776C patent/NL300776I1/nl unknown
- 2015-12-02 HU HUS1500063C patent/HUS1500063I1/hu unknown
- 2015-12-04 FR FR15C0083C patent/FR15C0083I2/fr active Active
- 2015-12-07 CY CY2015050C patent/CY2015050I2/el unknown
- 2015-12-08 LU LU92902C patent/LU92902I2/xx unknown
- 2015-12-08 LT LTPA2015049C patent/LTC1673106I2/lt unknown
- 2015-12-08 LT LTPA2015049D patent/LTPA2015049I1/lt unknown
- 2015-12-09 BE BE2015C072C patent/BE2015C072I2/nl unknown
-
2016
- 2016-02-04 JP JP2016019712A patent/JP2016136947A/ja active Pending
-
2017
- 2017-04-05 NO NO2017012C patent/NO2017012I1/no unknown
-
2022
- 2022-11-30 NO NO2022051C patent/NO2022051I1/no unknown